Home

THE FIRST FDA‑APPROVED, IN‑OFFICE TREATMENT FOR MOLLUSCUM

FOR AGES
2+

YCANTH™—a proven first‑line therapy for your patients

Photo is illustrative and not representative of all patients.

YCANTH achieved complete clearance within 12 weeks1

In two phase 3 clinical trials, significantly more YCANTH-treated patients experienced complete clearance of lesions than with vehicle within 12 weeks (P<0.0001)1,2

CAMP-13

46% vs 18%
(P<0.0001)

CAMP-23

54% vs 13%
(P<0.0001)

CAMP-1/CAMP-2=Cantharidin Application in Molluscum Patients-1 and -2.

Applicator

Applicator is not to scale.

YCANTH—precise control with proven results2

What you should know before administering YCANTH4

  • Verrica is committed to providing a training program to ensure an optimal experience
  • Counsel your patients to avoid contact with the treatment areas, including oral contact
  • Please review Instructions for Use and see Important Safety Information throughout
  • Advise patients to read Patient Information

Efficacy data

YCANTH—demonstrated efficacy with precise administration2

DISCOVER THE DATA

Applying YCANTH

Information for healthcare professionals (HCPs) on how to use YCANTH

LEARN TO USE YCANTH

Ways to access YCANTH

Acquisition options designed for your practice

GET STARTED

Copay Assistance Program

With the YCANTH Copay Assistance Program, eligible, commercially insured patients may save on treatment

SEE WHO QUALIFIES

Photos are illustrative and not representative of all patients.

Y-Access™ Support Solutions white glove service provides:

  • Assistance with benefit investigations and prior authorizations
  • Details about prior authorization requirements and appeals
  • Exploration of financial assistance options for Buy & Bill providers
  • Billing and coding support from Field Reimbursement Managers (FRMs), including claim submissions and resubmissions, if needed

For more information or assistance, contact Y-Access Support Solutions by calling 1-855-YCANTHS (1-855-922-6847) OR by visiting Y-AccessSupport.com.

Nurse On iPad

Model is for illustrative purposes only.

Stay informed about YCANTH

SIGN UP FOR UPDATES

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: None.

WARNINGS AND PRECAUTIONS:

  • YCANTH is for topical use only. YCANTH is not for oral, mucosal, or ophthalmic use. Life threatening or fatal toxicities can occur if YCANTH is administered orally. Avoid contact with the treatment area, including oral contact, after treatment. Ocular toxicity can occur if YCANTH comes in contact with eyes. If YCANTH gets in eyes, flush eyes with water for at least 15 minutes.

INDICATION

YCANTH (cantharidin) topical solution, 0.7% is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: None.

WARNINGS AND PRECAUTIONS:

  • YCANTH is for topical use only. YCANTH is not for oral, mucosal, or ophthalmic use. Life threatening or fatal toxicities can occur if YCANTH is administered orally. Avoid contact with the treatment area, including oral contact, after treatment. Ocular toxicity can occur if YCANTH comes in contact with eyes. If YCANTH gets in eyes, flush eyes with water for at least 15 minutes.
  • Local Skin Reactions: Reactions at the application site may occur, including vesiculation, pruritus, pain, discoloration, and erythema. Avoid application near eyes and mucosal tissue, and to healthy skin. If YCANTH contacts any unintended surface, or healthy skin, immediately remove. If severe local skin reactions occur, remove prior to the recommended 24 hours after treatment.
  • YCANTH is flammable, even after drying. Avoid fire, flame or smoking near lesion(s) during treatment and after application until removed.

ADVERSE REACTIONS:

The most common (incidence ≥1%) reactions are the following local skin reactions at the application site: vesiculation, pain, pruritus, scabbing, erythema, discoloration, application site dryness, edema, and erosion. Local skin reactions at the application site were observed in 97% of subjects treated with YCANTH during clinical trials. These local skin reactions are expected and related to the anticipated blistering response of the skin to cantharidin.

DRUG INTERACTIONS:

No studies evaluating the drug interaction potential of cantharidin have been conducted.

USE IN SPECIFIC POPULATIONS:

Pregnancy: There are no available data with use of YCANTH in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Given that systemic exposure to cantharidin following topical administration is low, maternal use is not expected to result in fetal exposure to the drug.

Lactation: Avoid application of YCANTH topical solution to areas with increased risk for potential ingestion by or ocular exposure to the breastfeeding child.

OVERDOSAGE:

Oral ingestion of cantharidin has resulted in renal failure, blistering and severe damage to the gastrointestinal tract, coagulopathy, seizures, and flaccid paralysis.

Please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Verrica Pharmaceuticals Inc. at 1-877-VERRICA (1-877-837-7422), or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Local skin reactions are expected and should be reported if they are severe.